| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 176 | 2022 |
| Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk E Muzurović, DP Mikhailidis, C Mantzoros Metabolism 119, 154770, 2021 | 145 | 2021 |
| Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors E Muzurović, CCH Peng, MJ Belanger, D Sanoudou, DP Mikhailidis, ... Hypertension 79 (7), 1319-1326, 2022 | 67 | 2022 |
| Homocysteine and diabetes: role in macrovascular and microvascular complications E Muzurović, I Kraljević, M Solak, S Dragnić, DP Mikhailidis Journal of Diabetes and its Complications 35 (3), 107834, 2021 | 60 | 2021 |
| Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic … EM Muzurović, Š Volčanšek, KZ Tomšić, A Janež, DP Mikhailidis, M Rizzo, ... Journal of Cardiovascular Pharmacology and Therapeutics 27, 10742484221146371, 2022 | 32 | 2022 |
| Can we decrease epicardial and pericardial fat in patients with diabetes? EM Muzurović, S Vujošević, DP Mikhailidis Journal of cardiovascular pharmacology and therapeutics 26 (5), 415-436, 2021 | 27 | 2021 |
| Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile E Muzurović, DP Mikhailidis Expert Opinion on Pharmacotherapy 21 (17), 2125-2135, 2020 | 23 | 2020 |
| Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern … A Janez, E Muzurovic, AP Stoian, M Haluzik, C Guja, L Czupryniak, ... International journal of cardiology 365, 8-18, 2022 | 20 | 2022 |
| Inflammatory markers associated with diabetes mellitus–old and new players E Muzurović, Z Stanković, Z Kovačević, BŠ Škrijelj, DP Mikhailidis Current pharmaceutical design 27 (27), 3020-3035, 2021 | 16 | 2021 |
| Weight-centric pharmacological management of type 2 diabetes mellitus–An essential component of cardiovascular disease prevention E Muzurović, S Dragnić, S Medenica, B Smolović, P Bulajić, ... Journal of Diabetes and its Complications, 107619, 2020 | 15 | 2020 |
| Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease—Pathogenesis and Pharmacological Treatment Options EM Muzurović, DP Mikhailidis Journal of Cardiovascular Pharmacology and Therapeutics 26 (1), 25-39, 2021 | 14 | 2021 |
| The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a … IC Bica, RA Stoica, T Salmen, A Janež, Š Volčanšek, D Popovic, ... Medicina 59 (6), 1136, 2023 | 13 | 2023 |
| Non-alcoholic fatty liver disease in children E Muzurović, SA Polyzos, DP Mikhailidis, S Borozan, D Novosel, ... Current Vascular Pharmacology 21 (1), 4-25, 2023 | 12 | 2023 |
| Commentary: from mice to men: in search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based E Muzurović, DP Mikhailidis, C Mantzoros Metabolism-Clinical and Experimental 109, 2020 | 11 | 2020 |
| Steatotic liver disease: pathophysiology and emerging pharmacotherapies M Kokkorakis, E Muzurović, Š Volčanšek, M Chakhtoura, MA Hill, ... Pharmacological reviews 76 (3), 454-499, 2024 | 7 | 2024 |
| A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis T Salmen, LI Serbanoiu, IC Bica, C Serafinceanu, E Muzurović, A Janez, ... International Journal of Molecular Sciences 24 (11), 9760, 2023 | 7 | 2023 |
| Timing is important—Management of metabolic syndrome according to the circadian rhythm K Zečević, N Popović, A Vuksanović Božarić, M Vukmirović, M Rizzo, ... Biomedicines 11 (4), 1171, 2023 | 6 | 2023 |
| Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? RV Giglio, EM Muzurović, AM Patti, PP Toth, MA Agarwal, W Almahmeed, ... Journal of Cardiovascular Pharmacology and Therapeutics 28, 10742484231186855, 2023 | 5 | 2023 |
| Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patients E Muzurović, M Rizzo, DP Mikhailidis Journal of Diabetes and its Complications 36 (12), 108359, 2022 | 5 | 2022 |
| Epicardial adipocyte-derived TNF-α modulates local inflammation in patients with advanced coronary artery disease E Muzurović, M Cojić, Z Stanković, A Janež Current Vascular Pharmacology 20 (1), 94-95, 2022 | 5 | 2022 |
Mantzoros ChristosHarvard在 bidmc.harvard.edu 的电子邮件经过验证
